The protection effect of trimetazidine on patients with diabetic cardiomyopathy
10.3760/cma.j.issn.1008-6706.2009.s1.001
- VernacularTitle:曲美他嗪对糖尿病心肌病患者的保护效应
- Author:
Xiaoxia ZOU
;
Sanli DAN
- Publication Type:Journal Article
- Keywords:
Diabetes complications;
Trimetazidine;
Myocardium;
Echocardiography
- From:
Chinese Journal of Primary Medicine and Pharmacy
2009;16(z1):1-3
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the protection effect of trimetazidine on patients with diabetic cardiomyopathy.Collection in January 2005～2008 in my years in October inpatient and outpatient services and long-term use of trimetazidine in patients with diabetic cardiomyopathy a total of 121 cases,divided by age:A group (the control group,59 people),B group ( treatment group,62 people),both groups with conventional medical treatment before and after treatment measured in fasting blood glucose,OGTT after 2 h blood glucose,blood lipids (total cholesterol,triglycerides),prothrombin time (PT),KPTT activation time (APTT),electrocardiogram QT dispersion,high-sensitivity C-reactive protein,blood pressure,ejection fraction (EF),left ventricular fractional shortening (FS),and compared before and after treatment LVMI (left ventricular mass index) and RWT (relative Room wall thickness).The results compared with those before treatment,B group significantly improved clinical symptoms,EF and FS compared to no significant difference,lowering blood lipids,blood glucose decreased,compared with A group,B group electrocardiogram QT dispersion has improved,B group LVMI,RWT ,high-sensitivity C-reactive protein lower than the A group (P<0.05);conclusions trimetazidine supplement the treatment of diabetic cardiomyopathy.
